Takeda partners with Zydus to develop chikungunya vaccine

pharmafile | September 20, 2016 | News story | Manufacturing and Production, Research and Development Takeda, Zydus Cadila, chikungunya 

Zydus Cadila has teamed up with Takeda to develop a vaccine for the chikungunya virus.

Zydus Cadila’s group firm Cadila Healthcare said in a BSE filing: “The broad-based agreement includes early stage development to the final commercialisation of the vaccine. There is currently no vaccine to prevent or medicine to treat chikungunya virus infection,”

Chikungunya is a mosquito-borne viral disease that causes fever and severe joint pain and has seen sporadic outbreaks across Asia, Europe and the Americas. The Japanese pharma giant will partner with the Indian firm to develop the first preventative measure for the illness.

 “By partnering with Takeda on this very important research and development initiative and leveraging our development capabilities, we will be taking an all-important step to prevent the disease burden,” commented Zydus group chairman and MD, Pankaj R Patel.

Takeda Vaccines COO Rahul Singhvi added: “Takeda is the centre of important vaccine-related activities in global health and emerging infectious diseases. This is another demonstration of Takeda’s major commitment to the health of children in developing countries and elsewhere around the world.”

Matt Fellows

Related Content

FDA grants Priority Review for Takeda’s cTTP treatment

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has …


Takeda collaboration to optimise biopharmaceutical manufacturing announced

A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering …

Takeda building

Takeda’s lung cancer drug granted FDA priority review

The FDA has granted priority review for Takeda’s New Drug Application (NDA) for its mobocertinib …

Latest content